Liraglutide as a means of modifying cardiometabolic risk in patients with arterial hypertension and concomitant obesity

Simple item page
dc.contributor.authorДунаєва, Інна Павлівна
dc.contributor.authorDunaieva, Inna
dc.date.accessioned2025-11-23T10:22:37Z
dc.date.issued2025
dc.descriptionBackground. Arterial Hypertension (AH), in combination with OBesity (OB), significantly increases cardiometabolic risk, leading to the development of cardiovascular events, chronic kid-ney disease, and metabolic disorders. In such patients, the effectiveness of standard antihyperten-sive therapy may be insufficient, which requires the use of drugs with pleiotropic action. Aim. To assess the effectiveness of liraglutide, Glucagon-Like Peptide-1 Receptors Agonist (GLP-1RA), as a component of combination therapy in patients with AH and OB, with the deter-mination of its effect on cardiometabolic status, functional state of the kidneys, heart and neuro-humoral regulation. Materials and Methods. The study involved 62 patients with AH and OB who received li-raglutide at a dose of up to 3.0 mg/day for 12 months. The dynamics of anthropometric, biochem-ical, hormonal, hemodynamic, and echocardiographic parameters were assessed. Statistical pro-cessing was performed using the Statistica 13.0 package (StatSoft Inc., USA). Results. During the treatment, a significant decrease in systolic and diastolic blood pressure, body mass index, insulin levels, leptin, Cardiotrophin-1 (CTF-1), N-terminal propeptide of brain natriuretic hormone (NT-proBNP), as well as an improvement in the lipid profile were observed. According to echocardiography, regression of myocardial hypertrophy and improved systolic and diastolic function of the left ventricle was recorded. Positive but insignificant dynamics of func-tional renal parameters were noted. Conclusions. Liraglutide demonstrates a pronounced multicomponent efficacy in patients with hypertension and obesity, reducing leptin resistance and improving neuroendocrine regula-tion and metabolic and hemodynamic profile. Our findings suggest that it can be used in complex therapy to modify cardiometabolic risk.
dc.identifier.citationDunaieva I. P. Liraglutide as a means of modifying cardiometabolic risk in patients with arterial hypertension and concomitant obesity / I. P. Dunaieva // Inter Collegas. – 2025. – Vol. 12 (2). – P. 21–28.
dc.identifier.issn2409-9988
dc.identifier.urihttps://repo.knmu.edu.ua/handle/123456789/37092
dc.language.isoen
dc.publisherХНМУ
dc.subject2025а
dc.subjectleptin
dc.subjectGLP-1RA
dc.subjectN-terminal propeptide of brain natriuretic hormone
dc.subjectcardiohe-modynamics
dc.titleLiraglutide as a means of modifying cardiometabolic risk in patients with arterial hypertension and concomitant obesity
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Dunaieva I.P. Liraglutide as a means of modifying cardiometabolic risk in.pdf
Size:
230.65 KB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
11.22 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Наукові праці. Кафедра клінічної фармакології та внутрішньої медицини